文献速递血栓与止血贫血与红细胞疾病

TK216(第一代EWS::FLI1融合蛋白拮抗剂)治疗尤文肉瘤的开放标签、多中心、I/II期首次人体试验

Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.
PubMed 文献 · J Clin Oncol · 2024-07-02

这项开放标签、多中心、I/II期首次人体试验在85例复发/难治性尤文肉瘤患者中评估TK216(一种直接结合EWS::FLI1的融合蛋白拮抗剂)。14天持续静脉输注TK216 200 mg/m2每日一次被确定为推荐II期剂量;在该剂量下耐受性良好,但活性有限,6个月无进展生存率为11.9%。

要点

  • TK216为直接结合EWS::FLI1融合蛋白的首次人体试验药物,联合长春新碱在临床前模型显示协同活性。
  • 14天持续静脉输注TK216 200 mg/m2每日一次被确定为推荐II期剂量。
  • 在推荐II期剂量下活性有限,6个月无进展生存率为11.9%。

核心结论

  • TK216以14天持续输注给药,联合或不联合长春新碱,耐受性良好,在复发/难治性尤文肉瘤的推荐II期剂量下显示有限活性。

研究设计与样本

  • 开放标签、多中心、I/II期首次人体试验,采用3+3设计,并在推荐II期剂量(RP2D)下设置扩展队列。
  • 共纳入85例复发/难治性尤文肉瘤患者,中位年龄27岁(范围11-77岁)。
  • TK216通过静脉持续输注给药,分为11个队列;给药持续时间从7天 later 延长至10、14和28天。
  • 从第2周期第1天起,研究者可选择加用长春新碱。

主要发现

  • 14天输注TK216的最大耐受剂量为200 mg/m2每日一次,在第9队列确定并选为RP2D。
  • 既往中位全身治疗方案数为三线(范围1-10)。
  • 在RP2D治疗的患者中,最常见相关不良事件包括中性粒细胞减少(44.7%)、贫血(29.4%)、白细胞减少(29.4%)、发热性中性粒细胞减少(15.3%)、血小板减少(11.8%)和感染(17.6%)。
  • 在第9和第10队列中,2例患者达完全缓解,1例达部分缓解,14例达疾病稳定;6个月无进展生存率为11.9%。
  • 第11队列的8例患者中无缓解。

关键数值与推荐

  • 14天输注TK216的RP2D为200 mg/m2每日一次。
  • RP2D治疗患者中最常见相关不良事件:中性粒细胞减少44.7%、贫血29.4%、白细胞减少29.4%、发热性中性粒细胞减少15.3%、血小板减少11.8%、感染17.6%。
  • 第9和第10队列中,2例完全缓解、1例部分缓解、14例疾病稳定;6个月无进展生存率11.9%。
  • 第11队列8例患者中无缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ewing Sarcoma (ES), a rare cancer with a pathognomonic translocation resulting in the Ewing sarcoma gene (EWS)::FLI1 oncoprotein, has a poor prognosis in the relapsed/refractory (R/R) setting. Tokalas (TK)216 was designed to bind EWS::FLI1 proteins directly, disrupt protein-protein interactions, and inhibit transcription factor function. TK216 plus vincristine showed synergistic activity in preclinical tumor models. To our knowledge, we report the results of a first-in-class, first-in-human phase I/II trial of TK216 in R/R ES. PATIENTS AND METHODS: TK216 was administered intravenously as a continuous infusion to patients with R/R ES in 11 cohorts. The dosing duration of 7 days was later extended to 10, 14, and 28 days. Vincristine could be added on day 1 after cycle 2, per investigators' choice. The trial used a 3 + 3 design with an expansion cohort at the recommended phase II dose (RP2D). RESULTS: A total of 85 patients with a median age of 27 years (range, 11-77) were enrolled. The maximum tolerated dose for the 14-day infusion of TK216, 200 mg/m2 once daily, was determined in cohort 9 and selected as the RP2D. The median previous number of systemic therapies regimens was three (range, 1-10). The most frequent-related adverse events in patients treated at the RP2D included neutropenia (44.7%), anemia (29.4%), leukopenia (29.4%), febrile neutropenia (15.3%), thrombocytopenia (11.8%), and infections (17.6%). In cohorts 9 and 10, two patients had a complete response, one had a partial response, and 14 had stable disease; the 6-month progression-free survival was 11.9%. There were no responses among the eight patients in cohort 11. CONCLUSION: TK216 administered as 14-day continuous infusion with or without vincristine was well tolerated and showed limited activity at the RP2D in R/R ES.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Meyers PA, Federman N, Daw N, et al. Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. J Clin Oncol. 2024. PMID: 38954782. doi:10.1200/JCO.24.00020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。